双重抑制KRASG12D和HSP90对抗KRASG12D抑制剂耐药性是有效的
Inés Pulido1, Laura C Gunder1, Chenghao Ying2
1University of Illinois at Chicago, Chicago, IL, United States.
Molecular cancer therapeutics
|October 23, 2025
概括
针对KRASG12D和HSP90的双抑制剂在抗药性癌症方面表现有前途. 这种方法克服了单独使用KRASG12D抑制剂的耐药性,为难以治疗的KRASG12D突变瘤提供了一种新策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- KRASG12D突变驱动各种癌症,抑制剂显示出临床前景.
- 药物耐药性,包括KRAS独立性和MAPK活性,限制了当前KRASG12D抑制剂的疗效.
- 在癌症中,HSP90被上调,对生存至关重要,使其成为潜在的治疗点.
研究的目的:
- 研究双重KRASG12D-HSP90抑制剂对KRASG12D突变癌症的疗效.
- 评估双抑制能否克服单剂KRASG12D抑制剂 (如MRTX1133.3) 中观察到的抗性.
- 探索阻力背后的分子机制以及双抑制对信号通路的影响.
主要方法:
- 使用KRASG12D突变的癌细胞系和患者衍生器官.
- 测试了临床阶段KRASG12D抑制剂 (MRTX1133) 和新型KRASG12D-HSP90双抑制剂的疗效.
- 评估了细胞亡,细胞活力和下游信号通路 (AKT,ERK1/2).
主要成果:
- MRTX1133的有效性各不相同,在一些模型中观察到显著的耐药性.
- 双重抑制剂KRASG12D-HSP90在诱导细胞亡和降低细胞活力方面表现出卓越的有效性.
- 双重抑制剂在耐药模型中有效抑制了关键的抵抗通路,如AKT和ERK1/2.
结论:
- 双重克拉斯格12D-HSP90抑制是对抗克拉斯格12D突变癌症的有效策略,包括耐药表型.
- 这种方法通过通过HSP90抑制来破坏癌细胞生存必需蛋白质的稳定性来解决抵抗机制.
- 双重抑制剂提供了一个有希望的治疗途径,以改善KRASG12D驱动癌症的临床结果.
相关概念视频
The Ras Gene
7.0K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
7.0K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Small GTPases - Ras and Rho
5.2K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
5.2K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K


